comparemela.com

Latest Breaking News On - ஜெனிபர் தென்கிழக்கு - Page 1 : comparemela.com

Data reflect disparities in use of next-generation sequencing for lung cancer

Patritumab deruxtecan demonstrates antitumor activity in patients with EGFR -mutant NSCLC

Patritumab deruxtecan induced a 39% overall response rate among patients with advanced, EGFR-mutant non-small cell lung cancer, according to phase 1 study results presented during the virtual ASCO Annual Meeting. “EGFR inhibitors are the standard of care for patients with advanced EGFR-mutant NSCLC. However, resistance inevitably develops, and the mechanisms of resistance are diverse. As

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.